NEW YORK, Dec. 6, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Ambit Biosciences Corporation. ("Ambit" or the "Company") (NasdaqGM: AMBI). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at email@example.com or 212-697-6484.
The investigation concerns whether Ambit and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On December 4, 2013, shares of Ambit fell $4.24 or 33.12% to close at $8.56 after the company announced after the market closed on December 3, 2013, that the Food and Drug Administration (FDA) would not accept the company's proposed novel surrogate endpoints, and therefore, Ambit would need to undertake a full Phase III clinical trial to prove the efficacy of Quizartinib, an oncology therapy being developed by the company.
If you are aware of any facts relating to this investigation, or purchased shares of Ambit, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC